Biomerica vs Cerenome
Cerenome is the larger business, with $5.2m of revenue in fiscal 2025 against $4.5m for Biomerica (1.2 times as much). Cerenome grew faster (-10.5% against -16.2%). Biomerica kept more of each dollar of sales as profit: a net margin of -84.8% against -429.4%. Biomerica carries less debt relative to equity (0.0% against 18.8%).
| Latest fiscal year | BiomericaBMRA, 2026 | CerenomeCNSY, 2025 |
|---|---|---|
| Revenue | $4.5m | $5.2m |
| Revenue growth | -16.2% | -10.5% |
| Net income | −$3.8m | −$22.4m |
| Operating margin | -119.5% | -293.5% |
| Net margin | -84.8% | -429.4% |
| Return on equity | -112.1% | — |
| Free cash flow | −$3.4m | −$20.8m |
| Cash | $1.3m | $4.3m |
| Total debt | $0 | $750,000 |
| Debt to equity | 0.0% | 18.8% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 54 | 28 |
| Market value | $8.0m | $9.6m |
| Price vs our value range | — | — |
| Moat score | 10 (Weak) | 18 (Weak) |
| Insider trades, 12 months | 5 buys, 0 sales | 1 buys, 0 sales |